Objective: To objectively quantify how cerebral volume loss could assist with clinical diagnosis and clinical trial design in the behavioural variant of frontotemporal dementia (bvFTD).
INTRODUCTION
In an effort to address the need for improved diagnostic biomarkers for the behavioral variant frontotemporal dementia (bvFTD) , several studies have demonstrated the potential value of morphometric MRI analysis for diagnostic purposes [1] . Here, we performed a deformationbased morphometry (DBM) study of longitudinal MRI changes in bvFTD.
Unlike voxel-based morphometry (VBM) where sometimes erroneous tissue classification can lead to incorrect measurement of gray matter volume, DBM does not depend on the automated segmentation into gray matter, white matter and CSF [2] [3] [4] . Instead, it uses image contrast directly as an explicit representation of these distributions. The improvements on nonlinear image registration algorithms allow for matching the images locally based on similarities in contrast and intensities, making DBM more sensitive than VBM for subtle differences. In addition, the image processing tools used in this study have been designed to process data from multi-site studies to handle biases due to multi-site scanning and have been applied successfully to a number of multi-site projects [5] [6] [7] [8] .
In this study, our objectives were: to precisely quantify the magnitude and pattern of volume change in bvFTD as compared to cognitively normal controls (CNCs) using DBM that rely on robust registration methods, to compare the progression of atrophy between these two cohorts over one year follow-up and to identify the structures most sensitive to change and generate sample size estimates for these regions of interest (ROIs) for the design of future therapeutic trials in bvFTD.
METHODS
Participants. The frontotemporal lobar degeneration neuroimaging initiative (FTLDNI) was funded through the National Institute of Aging and started in 2010. The primary goals of FTLDNI are to identify neuroimaging modalities and methods of analysis for tracking frontotemporal lobar degeneration (FTLD) and to assess the value of imaging versus other biomarkers in diagnostic roles. The project is the result of collaborative efforts at three sites in North America. For up-to-date information on participation and protocol, please visit: http://memory.ucsf.edu/research/studies/nifd. Data was accessed and downloaded through the LONI platform in August 2018. We included bvFTD patients and CNCs from the FTLDNI database who had T1-weighted (T1w) MRI scans matching with each clinical visit. The inclusion criteria for bvFTD patients was diagnosis of possible or probable bvFTD according to the frontotemporal dementia (FTD) consortium criteria [9] . All subjects included provided informed consent and the protocol was approved by the institution review board at all sites.
Clinical assessment. All subjects were assessed in periodic visits (every 6 months) for clinical characteristics (motor, non-motor and neuropsychological performance) by site investigators. All T1w scans for each subject were pre-processed through our local longitudinal pipeline [10] .
Image denoising [11] , intensity non-uniformity correction [12] , and image intensity normalization into range (0−100) using histogram matching were performed. For each subject, each native T1w volume from each timepoint was linearly registered together to form a subjectspecific template, aligned with the ICBM152 template [13, 14] . Each T1w volume was then non-linearly registered to the ICBM152 template using ANTs diffeomorphic registration pipeline [15] . The quality of the registrations was visually assessed and cases that did not pass this quality control were discarded (n=16 scans). where DBM values are 193*229*193 Jacobian matrices for different subject timepoints. Dx is a categorical variable for bvFTD versus CNCs. Sex is also a categorical variable. ID and Site are categorical random effects. The term Dx:AGE denotes the interaction between diagnostic group and age. The Jacobian determinant from the DBM analysis (as a proxy of local atrophy) was the dependent variable and age, sex, and diagnosis were the independent fixed variables. The model also included an interaction term between diagnosis and age in order to assess the additional impact of age on bvFTD compared to CNCs. The resulting maps were corrected for multiple comparisons using False Discovery Rate (FDR) [16] , thresholded at 0.05 to identify regions associated with differences between bvFTD and CNCs.
Atlas-based analysis. In order to provide regional information on cerebral changes, an atlasbased analysis was also used to determine the mean volume difference of all cortical and subcortical structures. These structures were identified by manually defined labels based on the Mindboogle-101 labelling protocol registered to the ICBM152 template [17] . For each structure, the mean and SD of the Jacobian values (as a proxy for volume) for each cohort were determined. Then, a two-sample t-test for equal means was performed, comparing the two groups (corrected for age and sex).
The magnitude of atrophy (or expansion) per year was assessed performing multiple linear regressions on the average DBM Jacobian values per region for each group by age for subjects that had more than 1 visit (N=160; 53 bvFTD and 107 CNCs). The same procedure was implemented with the functional and cognitive scores to obtain the mean annual change and sample size estimates for each cohort.
Finally, using the differences in the mean annual rate of atrophy/enlargement between the two groups in each region, the sample sizes (per arm) necessary to detect a 25% reduction in yearly change due to disease were estimated for use in potential clinical trials (80% power and 5% 1tailed significance). All estimates were multiplied by 1.20 to account for 20% expected attrition.
Annual change in DBM Jacobian values was also correlated with the annual change in CDR-SOB for the structures with sample sizes smaller than 300.
RESULTS
Demographics. We included 203 subjects; 70 bvFTD and 133 CNCs with a total of 482 timepoints. Table 1 shows the demographic and cognitive testing performances in bvFTD and CNCs. There was no statistically significant difference in mean age between bvFTD patients vs CNCs (62.16.5 and 64.17.5 years respectively, p=0.06). There was a higher proportion of men in bvFTD patients than CNCs (67% vs 42%, p=0.001). The number of follow-up visits was comparable in the two cohorts, albeit a slightly longer follow-up time in controls vs bvFTD patients (1.15 [0.6-3] vs 1.0 [0.3-1.1] years respectively, p<0.001). As expected, bvFTD subjects showed greater cognitive and functional impairment. Significant differences were found between the two cohorts in MMSE, MOCA, CGI, language and behavior CDR, and both global score CDR and CDR-SOB sum of boxes (p<0.001). Complete neuropsychological test results for bvFTD and CNCs can be found in Table e -2 in the Supplemental Data. Figure 1 shows the statistically significant differences in local volume differences between bvFTD and CNCs after FDR correction. Greater gray and white matter atrophy is evident in the medial and inferior lateral portions of the frontal lobes as well as dorsolateral prefrontal cortex, insula, basal ganglia, medial and anterior temporal regions bilaterally and regions of brainstem and cerebellum in bvFTD. A corresponding volume increase is shown in the ventricles and sulci, being more evident in frontal horns and lateral sulcus. Restricted bilateral involvement of parietal cortex was also found, though with a lesser degree of atrophy.
Cross-sectional voxel-wise DBM analysis.
Longitudinal voxel-wise DBM analysis. Both bvFTD and CNCs showed predominant medial volume loss due to ageing affecting predominantly white matter ( Figure 2 ). When factoring this age-related volume loss, over a brief follow up period (median 1 year), the enlargement of the frontal horns of the ventricles was the most significant differentiator between bvFTD and CNCs ( Figure 3 ). However, significant atrophy, greater than expected for age, was also found in small areas across the cingulum, callosum and medial frontal cortex in the bvFTD group.
Cross-sectional atlas based DBM analysis.
Assessing the baseline differences per anatomically defined regions between the two cohorts, significant differences were found in a large number of regions with an antero-posterior gradient. The greatest magnitude of change found was the enlargement of lateral and third ventricles (p=<0.001, t>10) and atrophy of the thalamus (p=<0.001, t=-10.62), followed by significant atrophy of the amygdala, lateral orbitofrontal cortex and putamen (p=<0.001, t=-9.76, t=-9,69, t=-9.5 respectively). Table 2 shows the mean DBM Jacobian values, p-values and t-values for the structures with the largest (t-values  5) differences between bvFTD and CNCs after FDR correction. The complete table with all the statistically significant structures can be found in Supplemental data (table e-3) .
Annual change and sample size estimation. Table 3 lists the structures that showed significant differences in progression of atrophy/enlargement in the 1-year follow up; the mean annual changes of DBM per region for each cohort and the corresponding p-values. Many cortical and subcortical structures showed significant progression in atrophy (i.e., reduction in DBM Jacobian value) in bvFTD compared to CNCs. However, the greatest change in one year was associated to the enlargement of the ventricles with a mean annual change 4 to 10 times greater for bvFTD than CNCs for lateral ventricles, third ventricle and inferior lateral ventricles (p<0.001). As mentioned, statistically significant differences in the annual change between the groups were also found in several cortical and subcortical structures such as posterior cingulate, diencephalon, putamen and thalamus (p<0.001). 
DISCUSSION
The major findings of this study are: (1) subjects with bvFTD at baseline showed the expected atrophy in the frontal lobes (most evident in medial portions), insula, basal ganglia, medial and anterior temporal regions bilaterally both on voxel wise analysis and with anatomically defined ROIs approach; (2) subcortical structures were notably affected in our bvFTD cohort; (3) ventricles and sulci within frontotemporal regions were larger in bvFTD compared to CNC and showed significant enlargement and over a one year period. Ventricular expansion (particularly the lateral ventricles) was the most prominent differentiator of bvFTD from CNCs and thus could be a sensitive marker of disease progression.
From the cross-sectional perspective, the frontal and anterior temporal atrophy observed in bvFTD is consistent with previous post-mortem and voxel-based morphometric studies [18] [19] [20] .
Although we did not observe any significant atrophy in occipital lobes in the patients with bvFTD, we did find significant bilateral parietal involvement, though with lesser degree of atrophy compared to frontal and temporal structures. Of particular importance is the involvement of the amygdala and subcortical structures (thalamus, putamen, ventral diencephalon, accumbens area), which in our bvFTD cohort showed the greatest group differences, comparable only to lateral and third ventricle -also an expression of central atrophy -and insular, superior frontal and orbitofrontal cortices.
Over an overall median follow-up time of 1 year, the voxel-wise beta maps showed that the enlargement of the lateral ventricles was the most significant differentiator between bvFTD and CNCs. However, significant progression in atrophy was also found in small areas mainly across the cingulum and medial frontal cortex, consistent with previous longitudinal results with similar follow up period [21] . Unexpected positive values suggesting growth over time were observed for the left caudate (Table 3 ). This is likely due to a methodological error related to its prominent shrinkage and the corresponding sizeable enlargement of the lateral ventricles, leading to the contamination of the caudate signal with that from the ventricle through partial volume effects. This is a methodological limitation of voxel-based techniques, that has previously been observed in other studies as well [22, 23] .
According to a previously proposed clinicopathological scheme for staging FTD [24, 25] , our results are in concordance with stage 2, where progression of atrophy is focused in orbital and superior medial frontal cortex along with flattening of the caudate nucleus, and with stage 3 where the hallmark is the involvement of the basal ganglia and ventricles appear considerably dilatated.
Finally, we found that the ventricles played a remarkable role in discriminating bvFTD from controls and proved to be a sensitive indicator of disease progression. Although this has been suggested in a previous study with fewer bvFTD subjects [26] , our results further confirm these findings and prove the relevance of measuring ventricle enlargement, a finding frequently overlooked in clinical practice. The lateral ventricles appear to be the structure with the most substantial change in DBM Jacobian values per year. Figure 5 40% effect size using whole brain volume. Whereas 127 and 51 bvFTD subjects were estimated for 25% and 40% effect size respectively using ventricular volume (12-months trial, 80% power, 5% significance and 35% potential attrition rate) [26] . Their study reported 11.2% annual change in ventricular volume in a bvFTD cohort (N=34). In comparison, our slightly larger sample size for ventricular annual change could be in relation to different disease severity (our group is slightly older and has an MMSE of 23.6). As mentioned previously, the rate of progression is thought vary within stages. Other estimates have been made by Binney et al. where the smallest sample size reported is for data-driven ROIs compared to anatomically based ROIs with 409 and 103 subjects per arm for 20 and 40% reduction in rate of decline respectively (12-months trial, 80% power and 5% significance) [27] . Finally, a recent study reports a required sample of 163 bvFTD subjects for 40% effect size and 418 for 25% effect size using left frontal volume as an outcome measure (12-months trial, 80% power, 5% significance and 20% potential attrition rate) [28] ; these numbers are more than twice as large are those we estimate for the lateral ventricles. However, when using fractional anisotropy from the corpus callosum, they required only 94 subjects per arm but their estimate was based on diffusion data from a single site. Intersite variability of diffusion data may increase this number of multi-site trials. Consequently, our analysis shows that using annual change in ventricular volume measured by DBM as an outcome measure would require the smallest sample when using morphological data derived from standard T1w MR images. Despite being easier to segment, using larger structures such as whole brain or lobes will require more subjects per arm to detect reduction in the rate of decline. In other words, the use of larger structures may dilute the change signal if atrophy is localized to specific regions, resulting in bigger sample size estimates.
We acknowledge that there are limitations to the present study. First, the short period of followup and the lack of disease duration or time from diagnosis, which is not available in the data used for this study. Second, DBM is not the most reliable method to assess cortical changes and it is sensitive to partial volume effects. This was demonstrated with the positive values for longitudinal progression in the caudate and is also suspected to affect the effect size of the atrophy in the cortical regions due to sulcal enlargement. Third, compared to cortical thickness, conventional voxel-based techniques are a less sensitive measurement to detect regional gray matter changes related to neurodegeneration at early stages due to partial volume effects [29] .
However, DBM has the advantage of being less sensitive to white matter lesions which are remarkably present in the FTLDNI bvFTD cohort used in this study. Future work will complement these current results with cortical thickness measurements corrected the confounding impact of white matter lesions together with volumetric analysis in order to work out this methodological limitation.
In conclusion, we propose automated measurement of ventricular expansion as a sensitive and reliable marker of disease progression in bvFTD to be used in clinical trials for potential disease modifying drugs, as well as possibly to implement in clinical practice. 
